<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62" class="p">At present, the conventional Chagas Disease treatments are etiologic, and are comprised of only two possible options, Nifurtimox (NFX) (Lampit®, Bayer) and Benznidazole (BNZ) (Rochagan® in Brazil and Radanil® in Argentina, Roche). These two treatments have remained the standard since their introduction into clinical therapy more than 40 years ago [
 <xref ref-type="bibr" rid="CR6" class="xref">6</xref>]. As disadvantages, these treatments are highly toxic (often accompanied by serious side effects like digestive intolerance, severe anorexia and neurological disorders) [
 <xref ref-type="bibr" rid="CR7" class="xref">7</xref>]; involve prolonged treatment times; and demonstrate variable trypanocidal effectiveness in acute stage (with about 80% being associated with natural resistance). They also display limited efficacy in the late phase of the infection (in which the benefits of these therapies have not clearly defined) [
 <xref ref-type="bibr" rid="CR8" class="xref">8</xref>, 
 <xref ref-type="bibr" rid="CR9" class="xref">9</xref>].
</p>
